Home > Press > Iroko Pharmaceuticals Acquires Nano-Reformulated Products from iCeutica
Iroko Pharmaceuticals, LLC and iCeutica, Inc. announce Iroko's acquisition of worldwide rights to two products formulated by iCeutica's proprietary Encapsulated Organic Nanoparticle (EON™) Platform technology. In addition, Iroko and iCeutica will collaborate on the application of iCeutica's EON Platform to reformulate an internal proprietary Iroko product. Iroko will guide progression of these EON formulated products through the regulatory process and ultimate launch.
Iroko Pharmaceuticals Acquires Nano-Reformulated Products from iCeutica
Philadelphia, PA | Posted on July 1st, 2007
"We are very pleased to announce this collaboration with iCeutica. The EON formulated products Iroko has acquired can have significant, relevant benefits for patients, in enhancing onset of action and reducing side effects," said Iroko President and CEO, John Vavricka.
"This transaction represents our first major transaction with a Pharmaceutical Company and further validates the value proposition of the EON Platform. Our team is very impressed with Iroko's highly credible and experienced team and looks forward to Iroko driving the first EON reformulated product to market," stated iCeutica CEO, Matt Callahan.
About Iroko Pharmaceuticals, LLC
Iroko is a pharmaceutical company focused on specialty therapeutic areas. The company acquires, develops, and maximizes the potential of currently marketed pharmaceutical products. Iroko increases the revenues of acquired products through focused selling and marketing efforts and product life cycle management activities including development of relevant formulations to improve patient treatment.
About iCeutica Inc: iCeutica commercializes products developed utilizing their proprietary EON™ Platform. EON is an enabling reformulation technology which provides low cost solutions to extend the life cycle of marketed products, as well as to become a cornerstone drug delivery technique for new chemical entities. The EON Platform provides a simple and scalable process to reformulate a range of different drugs.
For more information, please click here
Lisa Gray, Managing Partner
Phoenix IP Ventures
Copyright © Iroko Pharmaceuticals, LLC
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014
Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014
RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014
Bipolar Disorder Discovery at the Nano Level: Tiny structures found in brain synapses help scientists better understand disorder October 22nd, 2014
Nanoparticle technology triples the production of biogas October 23rd, 2014
SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014
Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014
Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014
European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014
IRLYNX and CEA-Leti to Streamline New CMOS-based Infrared Sensing Modules Dedicated to Human-activities Characterization October 15th, 2014
New VDMA Association "Electronics, Micro and Nano Technologies" founded: Inaugural Meeting in Frankfurt/Main, Germany October 15th, 2014
VDMA photonics steering committee with new members stronger than ever October 14th, 2014